Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study
European Commission decision on the Marketing Authorisation Application expected in April 2021
DUBLIN, Ireland and BRIDGEWATER, NJ, USA I January 29, 2021 I Amarin Corporation plc (NASDAQ:AMRN) today announced that in response to Amarin’s Marketing Authorisation Application submission, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending that a marketing authorisation be granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA®.
The CHMP recommendation is now expected to be reviewed by the European Commission, which has the authority to approve medicines for marketing in the European Union. A decision by the European Commission is expected to take place within 67 days of the CHMP opinion.
“We thank the EMA for its thoughtful review of our application and concluding it in a timely manner despite the challenges imposed by COVID-19,” said Steven Ketchum, senior vice president, president of R&D and chief scientific officer of Amarin. “This positive CHMP opinion is a significant milestone for Amarin, taking us one step closer to making this important therapy available to millions of patients in the European Union at high risk of cardiovascular events such as heart attacks and strokes. We are dedicated to supporting a rethinking of cardiovascular disease risk reduction in Europe with further emphasis on preventative care.”
The CHMP opinion is based on over a decade of development and testing of icosapent ethyl, including data from the REDUCE-IT® cardiovascular outcomes study. REDUCE-IT evaluated more than 8,000 high risk patients who despite having their cholesterol levels well controlled by statin therapy remained at significant risk of heart attack, stroke, or other major adverse cardiovascular events (MACE), including death. As published, patients in the REDUCE-IT study had a median follow-up period of nearly five years. Results from this study, in which all patients remained treated by statins (and by other contemporary therapies) and where half the patients received icosapent ethyl and the other half received placebo, demonstrated a 25% relative risk reduction (p<0.001) in the first occurrence of MACE in the intent-to-treat patient population with use of icosapent ethyl (4 grams daily) compared with placebo.
Based on communications with the EMA we expect the indication language to be generally consistent with the following:
That marketing authorisation be granted to icosapent ethyl to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL), and
- established cardiovascular disease, or
- diabetes, and at least one other cardiovascular risk factor.
Ten years of market protection is expected to be granted in the European Union as part of a European Commission approval of the pending application. In addition, pending patent applications related to the REDUCE-IT study have the potential to extend exclusivity in Europe into 2039.
For more information about the CHMP announcement visit the EMA website (this link will take you to an external website) https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021
About Amarin
Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
SOURCE: Amarin
Post Views: 34
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study
European Commission decision on the Marketing Authorisation Application expected in April 2021
DUBLIN, Ireland and BRIDGEWATER, NJ, USA I January 29, 2021 I Amarin Corporation plc (NASDAQ:AMRN) today announced that in response to Amarin’s Marketing Authorisation Application submission, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending that a marketing authorisation be granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA®.
The CHMP recommendation is now expected to be reviewed by the European Commission, which has the authority to approve medicines for marketing in the European Union. A decision by the European Commission is expected to take place within 67 days of the CHMP opinion.
“We thank the EMA for its thoughtful review of our application and concluding it in a timely manner despite the challenges imposed by COVID-19,” said Steven Ketchum, senior vice president, president of R&D and chief scientific officer of Amarin. “This positive CHMP opinion is a significant milestone for Amarin, taking us one step closer to making this important therapy available to millions of patients in the European Union at high risk of cardiovascular events such as heart attacks and strokes. We are dedicated to supporting a rethinking of cardiovascular disease risk reduction in Europe with further emphasis on preventative care.”
The CHMP opinion is based on over a decade of development and testing of icosapent ethyl, including data from the REDUCE-IT® cardiovascular outcomes study. REDUCE-IT evaluated more than 8,000 high risk patients who despite having their cholesterol levels well controlled by statin therapy remained at significant risk of heart attack, stroke, or other major adverse cardiovascular events (MACE), including death. As published, patients in the REDUCE-IT study had a median follow-up period of nearly five years. Results from this study, in which all patients remained treated by statins (and by other contemporary therapies) and where half the patients received icosapent ethyl and the other half received placebo, demonstrated a 25% relative risk reduction (p<0.001) in the first occurrence of MACE in the intent-to-treat patient population with use of icosapent ethyl (4 grams daily) compared with placebo.
Based on communications with the EMA we expect the indication language to be generally consistent with the following:
That marketing authorisation be granted to icosapent ethyl to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL), and
- established cardiovascular disease, or
- diabetes, and at least one other cardiovascular risk factor.
Ten years of market protection is expected to be granted in the European Union as part of a European Commission approval of the pending application. In addition, pending patent applications related to the REDUCE-IT study have the potential to extend exclusivity in Europe into 2039.
For more information about the CHMP announcement visit the EMA website (this link will take you to an external website) https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021
About Amarin
Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
SOURCE: Amarin
Post Views: 34
